|
Torrent
seems to be emerging as a serious player in the Merck
generics deal. Sources say the company looks all geared
to take a big jump into the global generics space, tacitly
backed by willing private equity players, reports CNBC-TV18.
Sources
say that Torrent Pharma is backed by Greater Pacific and
Fortress Investment. They also state that top Torrent
officials are camping in Germany for the deal.
The
deal is valued at around USD 6 billion. Merck management
presentations were on this week. Those who are still in
the race for Merck include Actavis, Mylan and Teva. Sources
claim that due
diligence of short-listed bidders will be seen next week
onwards.
Torrent
Pharma is also looking at big global generic presence.
It has acquired Heumann Labs in Germany a few years ago
from Pfizer.
|
